WntResearch announces that the Phase 1b study with Foxy-5 is approved

WntResearch today announces that the Danish regulatory authorities and the ethics committee have approved the protocol for the Phase 1b study with Foxy-5. Thus, the study will start immediately.

With the Danish regulatory authorities and the ethics committee having approved the protocol for the previously announced Phase 1b study with Foxy-5, two Danish research centres (Rigshospitalet in Copenhagen and Herlev University Hospital), will now begin recruitment of patients for the study.

Furthermore, WntResearch can also announce that Northern Centre for Cancer Care (NCCC) at Freeman Hospital, Newcastle, UK has been included as a research center in the study. As previously announced R&D Centre at Skåne University Hospital in Lund, Sweden is also included in the study. Hence, when final approvals are achieved a total of four sites will be part of the study.

CEO Henrik Lawaetz comments: "We are very pleased that the Phase 1b study now will be initiated. The study will be followed by a randomized phase 2 study in cancer patients with no or minimal metastatic disease, but a high risk of disease recurrence. We are also pleased with the inclusion of NCCC in Newcastle in the study, and hope this will increase the patient inclusion rate.”

CMO Nils Brünner comments: “We expect that the phase 1b study will give us information that we will use to optimize the conditions for the upcoming Phase 2 study. It will be particularly interesting to analyze the new biomarkers that will be used to monitor the effects of Foxy-5."

For additional information please contact:
Henrik Lawaetz, CEO
E-mail: hl@wntresearch.com
Telephone: + 45 20135298

About WntResearch
WntResearch has entered the clinical development phase with the company's first drug candidate, Foxy-5, which in animal models has been shown to dramatically inhibit the spreading of tumors (metastasis). The company goal is to commercialize new drugs against tumor metastasis. WntResearch is based on research from Professor Tommy Andersson and his research group at Lund University. Their research is aimed at developing innovations based on the protein Wnt-5a and its role in cancer. In addition to Foxy-5, which is in phase 1 clinical development, the company has a preclinical development program - Box-5. WntResearch AB is a public company listed on AktieTorget.

For more information see http://www.wntresearch.com